FA
PPH icon

Fortis Advisors’s VanEck Pharmaceutical ETF PPH Stock Holding History

Fortis Advisors’s Portfolio PPH Stock Details PPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-12,571
Closed -$763K – 349
2019
Q1 		$763K Buy
12,571
+46
+0.4% +$2.72K 0.4% 32
2018
Q4 		$686K Buy
+12,525
New +$759K 0.42% 32

Other funds holding PPH

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OC
Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Fortis Advisors's PPH Position: Q2 2019 in Review

Fortis Advisors sold out of VanEck Pharmaceutical ETF (PPH) in Q2 2019, closing a stake of 12,571 shares — an estimated $763K sold.

Fortis Advisors first reported a position in PPH in Q4 2018 and held it in 2 quarters. The position peaked at $763K in Q1 2019. 41 funds tracked by Wall St. Rank hold PPH as of Q2 2019.

  • Fortis Advisors reported no remaining VanEck Pharmaceutical ETF position as of Q2 2019 after selling out during the quarter.
  • Fortis Advisors sold 12,571 VanEck Pharmaceutical ETF shares in Q2 2019, an estimated $763K.
  • Fortis Advisors first reported a position in VanEck Pharmaceutical ETF in Q4 2018 and held it in 2 quarters.
  • Fortis Advisors's VanEck Pharmaceutical ETF position peaked at $763K in Q1 2019.
  • 41 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2019.

Based on Fortis Advisors's 13F filing for Q2 2019, filed 12 Aug 2019.